The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.g

Pulmonary fibrosis

Publications

Major PP, Laurin S, Bettez P

Pulmonary fibrosis following therapy with melphalan: report of two cases.

Canadian Medical Association journal. 1980;123(3):197-202

Mufti GJ, Hamblin TJ, Gordon J

Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma.

Acta haematologica. 1983;69(2):140-1

Codling BW, Chakera TM

Pulmonary fibrosis following therapy with Melphalan for multiple myeloma.

Journal of clinical pathology. 1972;25(8):668-73

Scheidegger S

[Pulmonary fibrosis, recurrent vasculitis and multicentric carcinoma of the lung following cytostatic therapy with alkeran (author's transl)].

Verhandlungen der Deutschen Gesellschaft fur Pathologie. 1972;56:364-8

Taetle R, Dickman PS, Feldman PS

Pulmonary histopathologic changes associated with melphalan therapy.

Cancer. 1978;42(3):1239-45